Obesity Surgery

, Volume 18, Issue 11, pp 1430–1437 | Cite as

A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH)

  • Zobair M. Younossi
  • Mohammed Jarrar
  • Clare Nugent
  • Manpreet Randhawa
  • Mariam Afendy
  • Maria Stepanova
  • Nila Rafiq
  • Zachary Goodman
  • Vikas Chandhoke
  • Ancha Baranova
Research Article

Abstract

Background

Within the spectrum of nonalcoholic fatty liver disease (NAFLD), only patients with nonalcoholic steatohepatitis (NASH) show convincing evidence for progression. To date, liver biopsy remains the gold standard for the diagnosis of NASH; however, liver biopsy is expensive and associated with a small risk, emphasizing the urgent need for noninvasive diagnostic biomarkers. Recent findings suggest a role for apoptosis and adipocytokines in the pathogenesis of NASH. The aim of this study was to develop a noninvasive diagnostic biomarker for NASH.

Methods

The study included 101 patients with liver biopsies who were tested with enzyme-linked immunosorbent assay (ELISA)-based assays. Of these, 69 were included in the biomarker development set and 32 were included in the biomarker validation set. Clinical data and serum samples were collected at the time of biopsy. Fasting serum samples were assayed for adiponectin, resistin, insulin, glucose, TNF-alpha, IL-6, IL-8, cytokeratin CK-18 (M65 antigen), and caspase-cleaved CK-18 (M30 antigen).

Results

Data analysis revealed that the levels of M30 antigen (cleaved CK-18) predicted histological NASH with 70% sensitivity and 83.7% specificity and area under the curve (AUC) = 0.711, p < 10−4, whereas the predictive value of the levels of intact CK-18 (M65) was higher (63.6% sensitivity and 89.4% specificity and AUC = 0.814, p < 10−4). Histological NASH could be predicted by a combination of Cleaved CK-18, a product of the subtraction of Cleaved CK-18 level from intact CK-18 level, serum adiponectin, and serum resistin with a sensitivity of 95.45% sensitivity, specificity of 70.21%, and AUC of 0.908 (p < 10−4). Blinded validation of this model confirmed its reliability for separating NASH from simple steatosis.

Conclusions

Four ELISA-based tests were combined to form a simple diagnostic biomarker for NASH.

Keywords

Obesity NASH Biomarkers NASH diagnostics 

References

  1. 1.
    Ong J, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in obese patients. Obes Surg. 2005;15(3):310–5.PubMedCrossRefGoogle Scholar
  2. 2.
    Mulhall BP, Younossi ZM. Nonalcoholic steatohepatitis. Curr Treat Options Gastroenterol. 2004;7:423–30.PubMedCrossRefGoogle Scholar
  3. 3.
    Marchesini G, Bugianesi E, Forlani G, Marzocchi R, Zannoni C, Vanni E, et al. Non-alcoholic steatohepatitis in patients cared in metabolic units. Diabetes Res Clin Pract. 2004;63:143–51.PubMedCrossRefGoogle Scholar
  4. 4.
    Younossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol. 2004;38:705–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology. 2000;32:477–81.PubMedCrossRefGoogle Scholar
  6. 6.
    Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898–906.PubMedCrossRefGoogle Scholar
  7. 7.
    Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745–50.PubMedCrossRefGoogle Scholar
  8. 8.
    Miele L, Forgione A, Gasbarrini G, Grieco A. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Transl Res. 2007;149:114–25.PubMedCrossRefGoogle Scholar
  9. 9.
    Ratziu V, Giral P, Munteanu M, Messous D, Mercadier A, Bernard M, et al. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther. 2007;25:207–18.PubMedGoogle Scholar
  10. 10.
    Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut. 2006;55:415–24.PubMedCrossRefGoogle Scholar
  11. 11.
    Ribeiro PS, Cortez-Pinto H, Sola S, Castro RE, Ramalho RM, Baptista A, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol. 2004;99:1708–17.PubMedCrossRefGoogle Scholar
  12. 12.
    Baranova A, Gowder SJ, Schlauch K, Elariny H, Collantes R, Afendy A, et al. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg. 2006;16:1118–25.PubMedCrossRefGoogle Scholar
  13. 13.
    Shimada M, Kawahara H, Ozaki K, Fukura M, Yano H, Tsuchishima M, et al. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol. 2007;102:1931–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44:27–33.PubMedCrossRefGoogle Scholar
  15. 15.
    Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol. 2007;13:837–44.PubMedGoogle Scholar
  16. 16.
    de Bruin EC, van de Velde CJ, van de Pas S, Nagtegaal ID, van Krieken JH, Gosens MJ, et al. Prognostic value of apoptosis in rectal cancer patients of the dutch total mesorectal excision trial: radiotherapy is redundant in intrinsically high-apoptotic tumors. Clin Cancer Res. 2006;12:6432–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, et al. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res. 2007;13:3198–206.PubMedCrossRefGoogle Scholar
  18. 18.
    Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol. 1999;187:567–72.PubMedCrossRefGoogle Scholar
  19. 19.
    Ueno T, Toi M, Linder S. Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother. 2005;59:S359–62.PubMedCrossRefGoogle Scholar
  20. 20.
    Hastie T, Tibshirani R, Friedman JH. The elements of statistical learning. New York: Springer; 2003.Google Scholar
  21. 21.
    Younossi ZM, Gorreta F, Ong JP, Schlauch K, Giacco LD, Elariny H, et al. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int. 2005;25:760–71.PubMedCrossRefGoogle Scholar
  22. 22.
    Ramalho RM, Cortez-Pinto H, Castro RE, Sola S, Costa A, Moura MC, et al. Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. Eur J Gastroenterol Hepatol. 2006;18:21–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Ribeiro PS, Cortez-Pinto H, Sola S, Castro RE, Ramalho RM, Baptista A, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol. 2004;99:1708–17.PubMedCrossRefGoogle Scholar
  24. 24.
    Diehl AM. Lessons from animal models of NASH. Hepatol Res. 2005;33:138–44.PubMedCrossRefGoogle Scholar
  25. 25.
    Baranova A, Younossi ZM. Adipokines in non-alcoholic fatty liver diseases. In: Fantuzzi G, Mazzone T, editors. Adipose tissue and adipokines in health and disease. New York: Humana Press; 2007. p. 291–307.CrossRefGoogle Scholar
  26. 26.
    Garcia-Galiano D, Sanchez-Garrido MA, Espejo I, Montero JL, Costan G, et al. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg. 2007;17:493–503.PubMedCrossRefGoogle Scholar
  27. 27.
    Manco M, Marcellini M, Giannone G, Nobili V. Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am J Clin Pathol. 2007;127:954–60.PubMedCrossRefGoogle Scholar
  28. 28.
    Yalniz M, Bahcecioglu IH, Ataseven H, Ustundag B, Ilhan F, Poyrazoglu OK, Erensoy A. Serum adipokine and ghrelin levels in nonalcoholic steatohepatitis. Mediators Inflamm. 2006;2006:34295.PubMedCrossRefGoogle Scholar
  29. 29.
    Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Yagmur E, Trautwein C, Leers MP, Gressner AM, Tacke F. Elevated apoptosis-associated cytokeratin 18 fragments (CK-18Asp386) in serum of patients with chronic liver diseases indicate hepatic and biliary inflammation. Clin Biochem. 2007;40:651–5.PubMedCrossRefGoogle Scholar
  31. 31.
    Bantel H, Lugering A, Heidemann J, Volkmann X, Poremba C, Strassburg CP, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology. 2004;40:1078–87.PubMedCrossRefGoogle Scholar
  32. 32.
    Roth GA, Krenn C, Brunner M, Moser B, Ploder M, Spittler A, et al. Elevated serum levels of epithelial cell apoptosis-specific cytokeratin 18 neoepitope m30 in critically ill patients. Shock. 2004;22:218–20.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • Zobair M. Younossi
    • 1
    • 2
    • 3
  • Mohammed Jarrar
    • 2
    • 3
  • Clare Nugent
    • 1
    • 3
  • Manpreet Randhawa
    • 2
    • 3
  • Mariam Afendy
    • 1
    • 3
  • Maria Stepanova
    • 1
    • 3
  • Nila Rafiq
    • 1
    • 3
  • Zachary Goodman
    • 4
  • Vikas Chandhoke
    • 2
    • 3
  • Ancha Baranova
    • 1
    • 2
    • 3
  1. 1.Center for Liver DiseasesInova Fairfax HospitalFalls ChurchUSA
  2. 2.Center for the Study of Genomics in Liver Diseases, Molecular and Microbiology DepartmentGeorge Mason UniversityFairfaxUSA
  3. 3.Translational Research InstituteInova Health SystemFalls ChurchUSA
  4. 4.Armed Forces Institutes of PathologyWashington, DCUSA

Personalised recommendations